Windtree Contracts Chinese Firm to Make Evofem's Contraceptive

Dow Jones06-27

By Dean Seal

Windtree Therapeutics said it has contracted with a pharmaceutical manufacturer in China to produce Evofem Biosciences's hormone-free contraceptive product Phexxi at a low cost.

The biotechnology company, Evofem's sourcing partner for Phexxi since March, said Thursday that the contract should cut Phexxi's manufacturing costs by over 50% by the end of 2026.

Windtree expects to start seeing some revenue from the arrangement next year.

Early-stage manufacturing is set to begin later this year.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 26, 2025 16:57 ET (20:57 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment